Patient Guide: Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 7 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06049212
Status: ACTIVE_NOT_RECRUITING
Condition: Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Phase: PHASE1

Find a Study Location Near You

This study is available at 7 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Nagoya, Aichi-ken
  • Kashiwa, Chiba
  • Matsuyama, Ehime
  • • And 4 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily